Zenas BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zenas BioPharma, Inc. - overview
Established
2019
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Founded in 2019 by Lonnie Moulder Jr, and based in Massachusetts, US, Zenas BioPharma (USA) LLC operates as a biopharmaceutical company dedicated to developing and delivering immune-based treatments to people. In May 2024, Zenas BioPharma (USA) LLC raised USD 200. 15 million in Series C funding co-led by SR One, New Enterprise Associates, Norwest Venture Partners, Delos Capital Partners, and others. In September 2024, Zenas BioPharma, Inc.
raised USD 209 million in an IPO, selling 13. 23 million shares at USD 17 per share, within the expected USD 16-18 range, on the Nasdaq Global Select Market under the ticker symbol "ZBIO. " BioPharma, Inc. has granted the underwriters a 30-day option to purchase up to an additional 1.
98 million shares of common stock as part of the listing. Following the transaction, Xencor, Inc. retained a 7. 8% minority stake, Enavate Sciences retained a 7.
2% minority stake, SR One retained a 6. 7% minority stake, and Longitude Capital retained a 5. 2% minority stake, respectively. Zenas BioPharma is a clinical-stage biopharmaceutical company developing and commercializing immunology-based therapies for autoimmune diseases.
The company offers a portfolio of therapeutics in clinical development, targeting areas with significant unmet medical needs. Zenas provides transformative treatments to improve the lives of patients with autoimmune conditions. The company intends to use the May 2024 funding to support the mid to late-stage clinical trials for its lead product candidate drug, obexelimab bifunctional monoclonal antibody.
Current Investors
Fairmount Funds Management, Vivo Capital, Wellington Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.zenasbio.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Zenas BioPharma, Inc. - financials
| Fiscal Year Ended | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Zenas BioPharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Zenas BioPharma, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.